SenzaGen AB

Stockholm Stock Exchange SENZA.ST

SenzaGen AB Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 14.51 K

SenzaGen AB Net Cash Used Provided By Financing Activities is USD 14.51 K for the year ending December 31, 2023, a 390.08% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

SenzaGen AB Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 2.96 K, a -99.90% change year over year.
SenzaGen AB Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 3.00 M, a 3,451.67% change year over year.
SenzaGen AB Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 84.60 K, a -99.19% change year over year.
SenzaGen AB Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 10.48 M, a 3,701.90% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Stockholm Stock Exchange: SENZA.ST

SenzaGen AB

CEO	Mr. Peter Nahlstedt
IPO Date	Sept. 21, 2017
Location	Sweden
Headquarters	Building 401
Employees	34
Sector	Consumers Staples
Industries Personal Care 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Cosmetics Plastics Pollution Treatment

Description

SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.

Key trends

Past 5 years